ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

@article{Engelman2005ErbB3MP,
  title={ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.},
  author={Jeffrey A. Engelman and Pasi Antero J{\"a}nne and Craig Mermel and Joseph Pearlberg and Toru Mukohara and Christina M Fleet and Karen Cichowski and Bruce Evan Johnson and Lewis C. Cantley},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2005},
  volume={102 10},
  pages={3788-93}
}
Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer (NSCLC). The differences in intracellular signaling networks between gefitinib-sensitive and -resistant NSCLCs remain poorly understood. In this study, we observe that gefitinib reduces phospho-Akt levels only in NSCLC cell lines in which it inhibits growth. To elucidate the mechanism underlying this observation, we compared immunoprecipitates… CONTINUE READING
Highly Influential
This paper has highly influenced 19 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 285 extracted citations

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…